Apricus Biosciences, Inc.
08.11.2012 15:00
---------------------------------------------------------------------------
SAN DIEGO, 2012-11-08 15:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com) announced today that the Company will present at two
upcoming conferences.
Edward Cox, Vice President, Corporate Development, will present at The
BIO-Europe 2012 Conference, being held at the CCH Congress Center in Hamburg,
Germany. Mr. Cox's presentation will take place on Tuesday, November 13, 2012
at 10:00 a.m. Central European Time.
Steve Martin, Interim Chief Executive Officer and Chief Financial Officer will
present at The Lazard Capital Markets 9th Annual Healthcare Conference, being
held at The Pierre Hotel in New York City. Mr. Martin's presentation will take
place on Wednesday, November 14, 2012 at 9:00 a.m. Eastern Time.
The Lazard presentation will be webcast and accessible online at
http://wsw.com/webcast/lz13/apri/ and that presentation, along with the
Bio-Europe presentation, will be available on the Company's website at
www.apricusbio.com. A replay of the webcasts will be available on the Company's
website for 14 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
high-demand therapeutic classes. The Company has four approved products and has
developed a strong pipeline of multiple late-stage product candidates. With
commercial operations in both the U.S. and Europe (France), Apricus Bio
generates revenues and growth from sales of its commercial products and by
out-licensing, in certain territories, its pipeline products and NexACT(r)
technology.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Takeda, Abbott Laboratories, Sandoz, Warner Chilcott, and Bracco, and
co-promotes multiple products in France.
Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
08.11.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences' Executives to Present at Two Upcoming Conferences
| Source: EQS Group AG